Related Experiment Video
Updated: Aug 5, 2026

Time-Lapse Epifluorescence Microscopy Imaging of Pseudomonas aeruginosa and Staphylococcus aureus Heterogeneous Phenotypes
Published on: February 14, 2025
The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance
Maria Cristina Caroleo1,2, Maria Pisano2, Erika Cione3
1CRUISE Research Center, Science of Health Department, University Magna Graecia, 88100 Catanzaro, Italy.
Abstract:
Background/Objectives: Persistent infections are characterized by recurrent treatment failure and relapse despite apparent antibiotic susceptibility by standard testing, a clinical reality not fully explained by conventional resistance paradigms. Bacterial persister cells, genetically susceptible but phenotypically tolerant subpopulations, survive otherwise lethal antibiotic exposure through reversible physiological adaptations. This review proposes a pharmacological framework linking antimicrobial exposure, bacterial tolerance, persistence, relapse, and the emergence of antimicrobial resistance (AMR). Methods: A structured narrative review was conducted using PubMed/MEDLINE, ClinicalTrials.gov, Centers for Disease Control and Prevention (CDC), and World Health Organization/Global Antimicrobial Resistance and Use Surveillance System (WHO/GLASS) sources (inception to 19 June 2026, priority 2010-2026), following Scale for the Assessment of Narrative Review Articles (SANRA) framework principles. Results: Resistance, tolerance, and persistence are pharmacologically distinct phenotypes. Persistence occurs without minimum inhibitory concentration (MIC) elevation and is shaped by antimicrobial exposure, target-site penetration, biofilm barriers, intracellular localization, and host stress. The review operationalizes persistence prevention exposure (PPE) in relation to minimum duration for killing 99%/99.99% of cells (MDK99/MDK99.99), persister fraction, minimum biofilm eradication concentration (MBEC), and biphasic time-kill modeling. Conclusions: Antimicrobial therapy should evolve from a model centered solely on MIC suppression and killing of actively growing bacteria toward one that also includes the prevention and eradication of persister reservoirs. Persistence prevention may reduce relapse, repeated antibiotic exposure, and the evolutionary path toward stable AMR.
Insights
Bacterial persister cells, though susceptible to antibiotics, can cause persistent infections. New strategies should focus on preventing persister cells to reduce relapses and the development of antimicrobial resistance (AMR).
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Persistent infections involve recurrent treatment failures and relapses, unexplained by standard antibiotic susceptibility testing.
- Bacterial persister cells are genetically susceptible but phenotypically tolerant subpopulations that survive antibiotic exposure via reversible physiological adaptations.
- Conventional resistance paradigms do not fully account for the clinical reality of persistent infections.
Purpose of the Study:
- To propose a pharmacological framework linking antimicrobial exposure, bacterial tolerance, persistence, relapse, and antimicrobial resistance (AMR).
- To operationalize persistence prevention exposure (PPE) using various antimicrobial exposure metrics.
- To advocate for a shift in antimicrobial therapy models.
Main Methods:
- A structured narrative review of scientific literature and surveillance data.
- Utilized databases such as PubMed/MEDLINE, ClinicalTrials.gov, CDC, and WHO/GLASS.
- Followed the Scale for the Assessment of Narrative Review Articles (SANRA) framework.
Main Results:
- Bacterial resistance, tolerance, and persistence are pharmacologically distinct phenotypes.
- Persistence occurs without an elevated minimum inhibitory concentration (MIC) and is influenced by factors like antimicrobial exposure, target penetration, biofilms, intracellular location, and host stress.
- Introduced concepts like persistence prevention exposure (PPE), minimum duration for killing (MDK), persister fraction, and minimum biofilm eradication concentration (MBEC).
Conclusions:
- Antimicrobial therapy must evolve beyond MIC suppression to include prevention and eradication of persister cell reservoirs.
- Preventing bacterial persistence may decrease infection relapse rates and reduce the need for repeated antibiotic courses.
- Targeting bacterial persistence could mitigate the evolutionary pathways leading to stable antimicrobial resistance (AMR).
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Microbiota Modulation by Antibiotics
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...

